Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?

Janneke Anink*, Marieke H. Otten, Simone L. Gorter, Femke H. M. Prince, Marion A. J. van Rossum, J. Merlijn van den Berg, Philomine A. van Pelt, Sylvia Kamphuis, Danielle M. C. Brinkman, Wijnand A. A. Swen, Joost F. Swart, Nico M. Wulffraat, Koert M. Dolman, Yvonne Koopman-Keemink, Esther P. A. H. Hoppenreijs, Wineke Armbrust, Rebecca ten Cate, Lisette W. A. van Suijlekom-Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?'. Together they form a unique fingerprint.

Keyphrases

INIS

Immunology and Microbiology